Presented at #EHA2026:
Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. Full phase 3 MonumenTAL-3 trial results: https://t.co/kqQAr539hL
@EHA_Hematology